Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Moderna call volume above normal and directionally bullish
Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%.
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Moderna beats on revenue but loses more than expected as it scales down manufacturing
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
TipRanks on MSN11h
Moderna’s 2024 Struggles: Navigating Commercial Challenges and Market Competition in the Vaccine Industry
Moderna (MRNA) has disclosed a new risk, in the Sales & Marketing category. Moderna faces significant commercial challenges, particularly in ...
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...
Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...
Moderna's Q4 Loss Wider Than Expected
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...